Hair on GLP-1

Part 1 · Hair · 1.17 min read · Updated Apr 21, 2026

Why You're Losing Hair on GLP-1 — And Why It's Not What You Think

Relevant forTitrationActive loss

Three to four months after starting semaglutide or tirzepatide, the shower drain starts telling a story. A thinner ponytail. A wider part. Millimeters of temple retreat that add up. Most of what you are seeing is reversible, predictable, and has a name — telogen effluvium. This chapter explains the biology, the timeline your body is moving through, and the single lever most GLP-1 users underestimate.

The short answer
  • What you are seeing is almost certainly telogen effluvium — a reversible, diffuse shed — not pattern baldness.
  • The medication is not toxic to hair follicles. The rapid weight loss and reduced protein intake it drives are.
  • Peak shedding hits at months 3 to 6. Regrowth is usually visible by months 6 to 12 if nutrition is addressed.
  • Scalp oils help, but the nutritional substrate — protein, iron, B12, vitamin D, zinc — is the limiting factor.
  • Escalate to a dermatologist if shedding continues past six months of stable weight, or if the pattern is a centered widening part.

Is this telogen effluvium — or something else?

Two different conditions show up in the GLP-1 community, and they are not the same thing.

Telogen effluvium (TE) — a reversible, diffuse shed that happens after a physical or metabolic stressor. Follicles leave the growth phase early, rest for about three months, then shed together. Hair regrows once the stressor resolves. This is what the large majority of GLP-1 hair loss cases are.

Androgenetic alopecia (AGA) — genetic pattern loss. Not reversible without intervention. Dermatologists have observed that rapid weight loss and hormonal shifts can unmask or accelerate AGA in predisposed individuals — but the GLP-1 is not causing AGA; it is revealing a tendency that was already there 1.

The distinction matters because the responses are different. TE responds to time, nutrition, and scalp care. AGA needs medical evaluation and usually pharmacological treatment. Vida is built for the first; the second belongs with a dermatologist.

Why GLP-1 triggers the shed

Semaglutide and tirzepatide do not appear to be directly toxic to hair follicles. What they do is produce the conditions that classically trigger TE.

Rapid weight loss. Bariatric surgery patients have been living with a version of this for decades; the literature has a name for it — bariatric surgery–induced telogen effluvium 2. GLP-1 therapy produces a similar metabolic stressor, especially when weight loss exceeds roughly 5% of body weight per month, sustained.

Reduced caloric and protein intake. When appetite drops 30 to 50% and stays there, total nutrition drops with it. Hair follicles are among the most metabolically demanding tissues in the body — when the body has to triage, hair production is an early casualty. Protein, iron, zinc, biotin, and vitamin D have each been mechanistically implicated in GLP-1-associated TE 3.

Systemic metabolic stress. Beyond nutrition, the sheer velocity of change in energy balance, insulin sensitivity, and adipose signaling is a meaningful physiological event. The hair cycle is sensitive to these shifts.

The 3-to-6-month timeline

Because telogen effluvium operates on a delay — follicles rest for roughly three months before shedding — the timing of what you see is predictable. The hair you notice falling in April was told to leave sometime in January.

  1. Month 1

    Appetite drops sharply. Caloric and protein intake fall. Follicles begin shifting into the resting phase.

    You notice nothing yet.

  2. Month 2

    Significant weight loss underway. More follicles entering rest.

    Minor increase in shedding, if any.

  3. Months 3–4

    The first wave of follicles that rested since month 1 now sheds.

    The “why is there so much hair in the drain” moment.

  4. Months 4–6

    Peak shedding phase for most people.

    Thinner ponytail. Wider part. More temple recession.

  5. Months 6–9

    If weight and nutrition have stabilized, new growth begins. Shedding subsides.

    “Baby hairs” along the hairline, at the part, on the scalp.

  6. Months 9–12+

    Recovery phase. Regrowth continues; new hairs thicken.

    Visible density improvement in most cases.

This timeline is typical, not guaranteed. People who continue to lose weight rapidly past month 6, or whose nutritional intake stays low, can develop chronic telogen effluvium — shedding that persists beyond six months 5. The chronic form is still reversible, but it requires resolving the driver, not waiting.

Nutrition is not optional

This is the line most GLP-1 users miss: you cannot solve GLP-1 hair loss with scalp care alone. The follicle is a factory. Factories need raw materials. When raw materials are chronically under-supplied, no amount of circulation-boosting topical will produce hair that is not being built.

The nutrients most directly implicated, based on the 2025 Journal of Cosmetic Dermatology review and adjacent literature on caloric restriction 3:

  • Protein — the substrate for keratin. Inadequate intake during rapid weight loss correlates directly with shedding.
  • Iron — especially relevant for premenopausal women. Low ferritin is one of the most common reversible drivers of diffuse hair loss.
  • Vitamin B12 — essential for the red blood cell production that carries oxygen to the scalp.
  • Vitamin D — a direct signaling role in the hair follicle cycle.
  • Zinc — cofactor for dozens of hair-cycle enzymes.

When to see a dermatologist

Topical care and nutrition handle the majority of GLP-1-associated hair loss. A dermatology consult is the right move when:

  • Shedding persists beyond six months of stable weight and adequate nutrition.
  • You see scarring on the scalp — shiny patches, visible skin where follicles should be, distinct round bald patches (possibly alopecia areata, a different condition).
  • The pattern is classic female-pattern loss — progressive thinning at the part and crown, widening central part, visible scalp in bright light.
  • You notice loss elsewhere on the body — brows, lashes — which can suggest an autoimmune process.
  • Your bloodwork shows significant deficiencies (low ferritin, low vitamin D, abnormal thyroid) that are not resolving.

A dermatologist can order trichoscopy, review labs, and discuss prescription options — topical or oral minoxidil, PRP therapy, spironolactone. Nothing in the Vida ritual is a substitute for any of these, and most dermatologists are comfortable with botanical scalp care running alongside prescribed treatment.

What to do
  1. 01

    Name it correctly.

    What you are seeing is almost certainly telogen effluvium — reversible, driven by metabolic stress and nutritional shift — not follicle damage from the drug.
  2. 02

    Expect the timeline.

    Peak shedding at months 3 to 6. Regrowth visible at months 6 to 12 for most people, if the drivers are addressed.
  3. 03

    Feed the follicle first.

    Protein, iron, B12, vitamin D, zinc. Framework in Chapter 4.1; personal framing in your Nutrition Companion.
  4. 04

    Add topical support second.

    Scalp care is an adjunct, not a substitute. The evidence behind rosemary and peppermint is covered in the next chapter.
  5. 05

    Know the escalation line.

    Persistent past six months, clearly patterned, or scarring — book a dermatologist. Topical care has a ceiling; pretending it doesn't costs you time.
Where to go from here
References
  1. [1]
    Buontempo MG, Alessandrini A, Starace M, Piraccini BM. Exploring the hair loss risk in glucagon-like peptide-1 agonists: Emerging concerns and clinical implications. J Eur Acad Dermatol Venereol. 2025. DOI: 10.1111/jdv.20512
  2. [2]
    Bariatric surgery-induced telogen effluvium (Bar SITE): case report and a review of hair loss following weight loss surgery. Cureus. 2021;13(4):e14617. DOI: 10.7759/cureus.14617
  3. [3]
    Alopecia and Semaglutide: Connecting the Dots for Patient Safety. Journal of Cosmetic Dermatology. 2025. PMC11909624
  4. [4]
    Godfrey H, Leibovit-Reiben Z, Jedlowski P, Thiede R. Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA Adverse Event Reporting System (FAERS) from 2022 to 2023. J Eur Acad Dermatol Venereol. 2024;39(2):e153–e154. DOI: 10.1111/jdv.20197
  5. [5]
    Hughes EC, Syed HA, Saleh D. Telogen Effluvium. StatPearls Publishing. Updated 2024. NCBI Bookshelf